Potent, Selective CARs as Potential T-Cell Therapeutics for HPV ...
2021年10月1日 · Here, we focus on a thoroughly studied immuno-oncology target, the HLA-A*02/HPV-E629-38 complex, and show that CARs can be optimized by a combination of high-throughput binding screens and low-throughput functional assays to have comparable activity to clinical TCRs in acute assays in vitro.
CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 …
2024年12月19日 · Ho and colleagues discovered a camel single-domain antibody, known as F5, that targets the oncogenic E6 of human papillomavirus (HPV) 16. Chimeric antigen receptor (CAR) T cells based on this nanobody showed promising efficacy in killing HPV16+ tumor lines and inhibiting tumor growth in cervical cancer xenografts in mice.
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV ...
We set out to test the limits of CAR pMHC screening and design, using HPV clinical TCRs as a comparator. Here, we provide a flow schema for making high-quality pMHC CARs. We use HPV as an example because of available benchmarks and other well-characterized reagents.
CAR T-cell Therapy for HPV-Induced Metastatic Cervical Cancer
2019年8月26日 · CAR T-cell therapy has been approved by the U.S. Food and Drug Administration (FDA) for certain hematologic malignancies. This early study demonstrates its effectiveness in human papillomavirus (HPV)-induced metastatic cervical cancer as well.
Engineered T cells targeting E7 mediate regression of human ... - JCI
The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV + cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV + cancers.
TCR-engineered T cells targeting E7 for patients with metastatic HPV ...
2021年2月8日 · Human papilloma virus (HPV)-associated malignancies, which include carcinomas of the uterine cervix, oropharynx, anus, vulva, vagina and penis, are prototypical epithelial cancers.
赶超CAR-T，TCR-T疗法成新一代抗癌利器！瞄准宫颈癌、肝癌、 …
2023年2月1日 · 嵌合抗原受体T细胞（CAR-T）疗法虽然在血液瘤里有非常好的疗效，但血液瘤仅占恶性肿瘤的10%，而占比高达90%的是实体瘤。 当在血液瘤中成功后，大家开始将CAR-T技术应用于实体瘤治疗但是阻力较多。 研究学者们纷纷开始尝试探索CAR-T以外的其他细胞疗法，包括NK（或CAR-NK）疗法、TCR-T疗法、TILs细胞疗法等。 今天无癌家园小编要讲的主角则是——TCR-T细胞疗法，即细胞受体基因工程改造的T细胞疗法。 个体化基因编辑+抗癌细胞疗法 …
T-cell Receptor–Engineered T Cells Show Efficacy in HPV
2021年5月1日 · A T-cell receptor T-cell therapy showed early promise in human papillomavirus (HPV)–linked cancers.
美研究显示，CAR-T细胞治疗可对HPV上皮癌有效 - 搜狐
2021年2月8日 · 人乳头瘤病毒（HPV）能引起人体皮肤黏膜的鳞状上皮增殖,导致上皮癌。 2021年2月8日，《自然-医学》发表了美国的一项研究。 该研究使用基因工程T细胞治疗转移性HPV相关上皮癌，获得了不错的治疗效果。 该研究纳入了12例患者，其中8例曾接受PD-1治疗、1例曾接受LN-145细胞治疗，效果均不理想。 研究人员对他们使用靶向T细胞受体的HPV-16 E7工程改造的T细胞（E7 TCR-T细胞）进行治疗，6例患者出现了明显的肿瘤消退, 包括4例PD-1疗效不理想的患者 …
高危型 HPV 检测纳入宫颈癌筛查方案；CAR-T疗法获美国FDA孤儿 …
2022年1月19日 · 近日，合源生物与中国医学科学院血液病医院联合宣布，靶向cd19的car-t药物cnct19细胞注射液获得美国fda授予的孤儿药资格（odd），用于治疗急性淋巴 ...